Quarterly ResultMay 5, 2026, 04:22 PM
Pacira Q1 Revenue $177M, +5%; Reaffirms 5x30 Strategy Amid Proxy Fight
AI Summary
Pacira BioSciences reported strong first-quarter 2026 results, with revenue increasing 5% to $177 million and Adjusted EBITDA reaching $40.2 million. The company highlighted the successful execution of its 5x30 strategy, which has seen its stock rise over 30% since its January 2025 launch, and reiterated its board's unanimous recommendation for its highly qualified nominees in the upcoming annual meeting. Pacira also announced $50 million in share repurchases during Q1, retiring approximately 2.2 million shares, and detailed progress across its product portfolio and pipeline, including significant growth in ZILRETTA and iovera° sales.
Key Highlights
- Q1 2026 revenue increased 5% to $177 million.
- Q1 2026 Adjusted EBITDA was $40.2 million.
- Repurchased $50 million in shares, retiring ~2.2 million in Q1.
- EXPAREL Q1 2026 net sales were $143.3 million.
- ZILRETTA Q1 2026 net sales grew 15% to $26.8 million.
- iovera° Q1 2026 net sales grew 21% to $6.2 million.
- Stock up over 30% since 5x30 strategy launch in January 2025.
- Ended Q1 with $202 million in cash and investments.
Price Impact
More from PCRX